2024
Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML
Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Goshua G, Bewersdorf J, Zeidan A. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leukemia & Lymphoma 2024, ahead-of-print: 1-9. PMID: 39560957, DOI: 10.1080/10428194.2024.2426073.Peer-Reviewed Original ResearchConventional care regimensOlder patientsTreatment of older patientsIDH2 inhibitor enasidenibIncremental cost-effectiveness ratioCost-effectiveness ratioProbabilistic sensitivity analysesR/R AMLRefractory/relapsed AMLEvent-freeCost-effective treatmentEnasidenibCare regimensAMLPatientsCost-effectiveIncremental costLife yearsConventional careR/RIncremental effectSurvivalTreatmentLoncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers.
Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington S, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith S, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson P, Grover N, Merril M, Crombie J, Shafagati N, Sterling C, Nastoupil L, Epperla N, Ayers E. Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers. Haematologica 2024, 0. PMID: 39540227, DOI: 10.3324/haematol.2024.285977.Peer-Reviewed Original ResearchLOTIS-2Overall response rateOverall survivalAntibody drug conjugatesBulky diseaseComplete responseRefractory diffuse large B-cell lymphomaUS centersDiffuse large B-cell lymphomaLarge B-cell lymphomaEvaluate outcomes of patientsHigh riskResponse rateB-cell histologyR/R DLBCL patientsPre-treated patientsB-cell lymphomaOutcomes of patientsProportion of patientsRetrospective cohort studyCell of originDLBCL patientsReal-world settingsRetrospective studyReal-world analysisReal World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma
Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.Peer-Reviewed Original ResearchT-cell lymphomaHeterogeneous group of lymphoid malignanciesGroup of lymphoid malignanciesPeripheral T-cell lymphomaAggressive T-cell lymphomaCutaneous T-cell lymphomaT cellsResponse rateR/R settingComplete responseLymphoid malignanciesPoor outcomeAnaplastic large cell lymphomaFrontline treatment regimensLarge cell lymphomaCombination of prednisoneHeterogeneous groupCell lymphomaChemotherapy optionsCaucasian patientsFirst-linePositive patientsTreatment regimensGrade 3LymphomaMedicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs . BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA)
Huntington S, Jawaid D, Marx S, Puckett J, Manzoor B, Li S, Emechebe N, Kamal-Bahl S, Ravelo A, Budlong H, Doshi J. Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs . BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s180. DOI: 10.1016/s2152-2650(24)00571-8.Peer-Reviewed Original ResearchReal-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors
Ravelo A, Patel A, To T, Li S, Huntington S. Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s180. DOI: 10.1016/s2152-2650(24)00569-x.Peer-Reviewed Original ResearchCLL-171 Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs. BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA)
Huntington S, Jawaid D, Marx S, Puckett J, Manzoor B, Li S, Emechebe N, Sachin-Bahl S, Ravelo A, Budlong H, Doshi J. CLL-171 Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs. BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s345-s346. DOI: 10.1016/s2152-2650(24)01265-5.Peer-Reviewed Original ResearchCLL-144 Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors
Ravelo A, Patel A, To T, Li S, Huntington S. CLL-144 Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s345. DOI: 10.1016/s2152-2650(24)01263-1.Peer-Reviewed Original ResearchPer-patient per-monthPer-patient per-month costsChronic lymphocytic leukemiaBruton tyrosine kinase inhibitorFirst-line treatmentTyrosine kinase inhibitorsLymphocytic leukemiaMonths 0Kinase inhibitorsHealthcare costsCLL/small lymphocytic lymphomaFixed-duration treatmentFirst-line therapyOff-treatment periodMonths post-indexMonths pre-indexRetrospective observational studyClinical trial enrollmentUS health planCommercially insured patientsLymphocytic lymphomaPrimary cancerFirst-linePost-indexIbrutinibReal-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting.
Huntington S, Manzoor B, Jawaid D, Puckett J, Emechebe N, Ravelo A, Kamal-Bahl S, Doshi J. Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting. Journal Of Managed Care & Specialty Pharmacy 2024, 30: 1106-1116. PMID: 39046941, PMCID: PMC11424914, DOI: 10.18553/jmcp.2024.24049.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaMonths 0Frontline settingSample of older US adultsMedicare beneficiariesLymphocytic leukemiaFee-for-service Medicare beneficiariesTreatment periodStudy of older adultsTyrosine kinase inhibitor useOlder US adultsBruton tyrosine kinase inhibitorFixed-duration therapyUS Medicare beneficiariesFee-for-serviceMonthly costTyrosine kinase inhibitorsHealth care costsMedicare Part ABcl-2 inhibitorsMultivariate general linear modelMonthly total costsTotal monthly costsPrescription drug costsComparison of health care costsCosts of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
Di M, Potnis K, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas. JNCI Cancer Spectrum 2024, 8: pkae059. PMID: 39115391, PMCID: PMC11340641, DOI: 10.1093/jncics/pkae059.Peer-Reviewed Original ResearchChimeric antigen receptor T-cell therapyB-cell lymphomaRelapsed/refractory B-cell lymphomaT-cell therapyCAR-T administrationCAR-T productsMedian total costCommercially insured patientsReal-world costsMedian costOut-of-pocket copaymentsCost of careLymphomaMonthly costTherapyPatientsProduct acquisitionFinancial outcomesHigher upfront costReal-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e350-e358.e1. PMID: 39034204, DOI: 10.1016/j.clml.2024.05.023.Peer-Reviewed Original ResearchR/R MCLOverall survivalTreatment patternsRelapsed/refractory mantle cell lymphomaReal-world treatment patternsBruton tyrosine kinase inhibitorCovalent Bruton tyrosine kinase inhibitorMantle cell lymphomaTyrosine kinase inhibitorsDevelopment of novel therapeuticsMCL patientsCell lymphomaThird-lineRetrospective studyTreatment initiationResponse durationAdverse eventsElderly patientsKinase inhibitorsPatient subpopulationsPatientsAll-causeNovel therapeuticsEconomic burdenSurvivalIntegrating 4 Methods (In4M) to evaluate physical function in patients with cancer: Results of a comprehensive digital health study.
Thanarajasingam G, Dueck A, Bhatnagar V, Brown A, Cathcart-Rake E, Diamond M, Faust L, Fiero M, Huntington S, Jeffery M, Jones L, Paludo J, Power B, Ross J, Ruddy K, Schellhorn S, Tarver M, Wood W, Gross C, Kluetz P. Integrating 4 Methods (In4M) to evaluate physical function in patients with cancer: Results of a comprehensive digital health study. Journal Of Clinical Oncology 2024, 42: 1564-1564. DOI: 10.1200/jco.2024.42.16_suppl.1564.Peer-Reviewed Original ResearchPhysical functionPF measuresDaily stepsClinically meaningful change scoresAverage daily stepsEvaluate physical functionDigital health studiesMeasures of PFWearable dataHealth StudyWalk testWeekend daysCore outcomeChange scoresPerformance statusTreatment toleranceDetect changesPearson correlationECOG performance statusBreast cancerEvaluate feasibilityCancer trialsSignificant declineData collectionBaselineOral cancer drug repositories: Challenges and solutions.
Sharath M, Huntington S, Halene S, Abdelghany O. Oral cancer drug repositories: Challenges and solutions. Journal Of Clinical Oncology 2024, 42: 11063-11063. DOI: 10.1200/jco.2024.42.16_suppl.11063.Peer-Reviewed Original ResearchCancer medicationsOral cancer medicationsLife saving treatmentOral cancer drugsTransfer of drugsDose modificationUnused pillsDrug repositoryState-level programsOral chemotherapyFrequent drug shortagesFederal fundingPatientsNational levelOncology drugsDonation ratesInterstate transferLawDrug recyclingCancer drugsDrugMedicationOut-of-pocket costsInsurance coverageReal-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study
Huntington S, Cheng W, Sarpong E, Leng S, Farooqui M, Agu U, Catillon M, Lejeune D, Downes N, Matay L, Duh M, De Nigris E. Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study. Leukemia & Lymphoma 2024, 65: 932-942. PMID: 38696747, DOI: 10.1080/10428194.2024.2331631.Peer-Reviewed Original ResearchSequential targeted therapyLymphocytic lymphomaTherapy useB-cell lymphoma 2 inhibitorChronic lymphocytic leukemia/small lymphocytic lymphomaBruton tyrosine kinase inhibitorTargeted therapy useSmall lymphocytic lymphomaChronic lymphocytic leukemiaTyrosine kinase inhibitorsProportion of patientsClaims-based studyFirst-lineLymphocytic leukemiaTargeted therapyClinical outcomesB cellsKinase inhibitorsTreatment sequenceReal-world patternsTherapyCLL/SLLBTKiCD20LymphomaCost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia
Bewersdorf J, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Stahl M, Stein E, Huntington S, Goshua G, Zeidan A. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia. Leukemia & Lymphoma 2024, 65: 1136-1144. PMID: 38648559, PMCID: PMC11265977, DOI: 10.1080/10428194.2024.2344052.Peer-Reviewed Original ResearchQuality-adjusted life yearsCompletion of consolidation therapyFLT3-mutant acute myeloid leukemiaAllogeneic hematopoietic cell transplantationIncremental cost-effectiveness ratioProbabilistic sensitivity analysesImproved overall survivalHematopoietic cell transplantationPartitioned survival analysis modelAcute myeloid leukemiaCost-effectiveness ratioFLT3 inhibitor quizartinibHealth economic implicationsConsolidation therapyInduction chemotherapyAverage wholesale priceOverall survivalCell transplantationContinuous therapyMyeloid leukemiaITD mutationQuizartinibIncremental costCost-effective optionLife yearsImmunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rateReal-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting
Garg M, Puckett J, Kamal-Bahl S, Raut M, Ryland K, Doshi J, Huntington S. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e181-e190. PMID: 38433043, DOI: 10.1016/j.clml.2024.01.010.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaHealthcare resource utilizationR-GemOxOverall survivalR/R settingR/R diffuse large B-cell lymphomaElderly patientsLarge B-cell lymphomaDLBCL diagnosisRates of healthcare resource utilizationCombination of rituximabMedian overall survivalR/R DLBCL patientsB-cell lymphomaStem cell transplantationReal-world survivalHealthcare resource useSample of patientsMicro AbstractRelapsed/refractory settingDLBCL patientsThird-lineSecond-lineCell transplantationPost-indexIntegrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study
Thanarajasingam G, Kluetz P, Bhatnagar V, Brown A, Cathcart-Rake E, Diamond M, Faust L, Fiero M, Huntington S, Jeffery M, Jones L, Noble B, Paludo J, Powers B, Ross J, Ritchie J, Ruddy K, Schellhorn S, Tarver M, Dueck A, Gross C. Integrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study. BMJ Open 2024, 14: e074030. PMID: 38199641, PMCID: PMC10806877, DOI: 10.1136/bmjopen-2023-074030.Peer-Reviewed Original ResearchConceptsPhysical function assessmentPhysical functionFunctional assessmentEvaluation of physical functionElectronic health record dataEvaluate physical functionHealth record dataSpanish-speaking patientsDigital health technologiesBreast cancerProspective cohort studyClinician-reported outcomesCancer clinical trialsClinical decision-makingStudy questionnairePatient-centred evaluationHealth technologiesMeasure symptomsOncology practiceCohort studyRecord dataPatient's impressionMayo ClinicEnglish-speakingWearable sensorsReal‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia
Huntington S, de Nigris E, Puckett J, Kamal‐Bahl S, Farooqui M, Ryland K, Sarpong E, Leng S, Yang X, Doshi J. Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia. Cancer Medicine 2024, 13: e6953. PMID: 38348963, PMCID: PMC10832339, DOI: 10.1002/cam4.6953.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaRate of adverse eventsIncidence rate of adverse eventsAdverse eventsPatient-monthsLymphocytic leukemiaIncidence ratePatients treated with ibrutinibTreatment of chronic lymphocytic leukemiaStandard-of-care therapyNon-discontinuationInitiation of ibrutinibBTK inhibitor ibrutinibAdverse event ratesPotential side effectsInhibitor ibrutinibMedicare beneficiariesReal-world analysisAtrial fibrillationFollow-upIbrutinibSide effectsReal-world outcomesEvent ratesLeukemiaRacial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States
Neparidze N, W. Lau K, Wang X, Huntington S, Jamy O, S. Calip G, Shah H, M. Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States. Medical Research Archives 2024, 12 DOI: 10.18103/mra.v12i2.5164.Peer-Reviewed Original ResearchAcute myelogenous leukemiaMantle cell lymphomaChronic lymphocytic leukemiaDiffuse large B-cell lymphomaFollicular lymphomaMultiple myelomaWhite patientsBlack patientsCell lymphomaHematologic malignanciesLymphocytic leukemiaTreatment categoriesElectronic health record (EHR)-derived de-identified databaseDiagnosis of acute myelogenous leukemiaLarge B-cell lymphomaTelemedicine uptakeActive patientsLines of therapyB-cell lymphomaMonthly visit ratesMyeloma patientsVisit ratesAnalyzed patientsMyelogenous leukemiaLymphoma
2023
Real-World Treatment Patterns, Survival, Health Resource use and Costs Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma
Garg M, Puckett J, Kamal-Bahl S, Raut M, Ryland K, Doshi J, Huntington S. Real-World Treatment Patterns, Survival, Health Resource use and Costs Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma. Future Oncology 2023, 20: 317-328. PMID: 38050764, DOI: 10.2217/fon-2023-0191.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaReal-world treatment patternsLarge B-cell lymphomaB-cell lymphomaTreatment patternsMedicare beneficiariesFirst-line treatmentFront-line treatmentHealthcare resource useHealth resource useElderly Medicare beneficiariesUnmet need existsOverall survivalR-CHOPMedicare patientsLater linesOlder adultsTreatmentPatientsLymphomaNeed existsSurvivalTwo-thirdsResource useSame period